Business Wire - Statement from Attorney James Morris of Brent Coon & Associates Regarding Jury’s Verdict in the Case of Simon Vs. Wyeth Et Al
PHILADELPHIA — “Once again, we have proven that postmenopausal hormone therapy causes breast cancer,” said attorney James A. Morris of the firm Brent Coon & Associates, commenting on the latest verdict in the nationwide hormone replacement therapy litigation. A Philadelphia jury found Pfizer Inc. (NYSE: PFE) liable for failing to properly warn New Jersey plaintiff Merle Simon’s physicians of the breast cancer risk posed by Provera, the progestin half of hormone replacement therapy. Pfizer was ordered to pay $1.5 million in damages. This trial was the first case to examine Provera’s “beagle dog warning,” determined by the jury to be inadequate.
Related Results
BrT to renounce to SMP service license.
Spain’s Telefonica eyes share of Telecom Italia
THE RISE OF TRONCHETTI PROVERA.(Pirelli’s Marco Tronchetti Provera)(Brief Art…
Riddett to Lead Pirelli’s Telecom Cables and Systems Activities; Robinson App…
Funny business.(Funny business)
Merle and Stephen Simon of West Orange, New Jersey brought this case against both Wyeth (NYSE: WYE) and Pfizer for their insufficient labels on their hormone therapy products Premarin, Prempro (Wyeth) and Provera (Pfizer). Both plaintiffs sat in the courtroom every day for the four weeks of trial.
Mrs. Simon took hormone replacement therapy from 1992-2002 and discontinued use of the drugs when she was diagnosed with breast cancer in 2002. While Wyeth escaped liability after two previous losses in Philadelphia finding Premarin and Prempro defective, the finding against Pfizer affirmed Wyeth CEO Robert Essner’s statement that the progestin side of the combination therapy may be the “bad actor”.
Attorneys James A. Morris, Jr. and Brian Ketterer of Brent Coon & Associates represented the Simons in this trial against Wyeth and Pfizer. Mr. Morris stated, “This verdict proves what we’ve suspected all along - that Essner is right, and the MPA is causing breast cancer. While we are disappointed that Wyeth was not, once again, held responsible, we respect the jury’s verdict and the excellent job they did considering the evidence over a four week trial. We believe this is an incredibly important verdict for women’s health. We remain committed to trying these cases and representing victims of these dangerous drugs.”
This is the third case to go to trial in Philadelphia. In the first two cases, Pfizer was not a defendant, and Wyeth was found liable in both cases.
COPYRIGHT 2007 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
